Adicet Bio, Inc. shareholders approved Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm at the 2026-06-17 meeting.
“Votes For Votes Against Abstain Broker Non-Votes 6,719,352 25,206 1,611 N/A”
Adicet Bio, Inc. — fact timeline
Source-grounded facts extracted from Adicet Bio, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Adicet Bio, Inc. shareholders approved Non-Binding Advisory Vote on Compensation of the Company’s Named Executive Officers at the 2026-06-17 meeting.
“Votes For Votes Against Abstain Broker Non-Votes 4,611,540 745,537 4,939 1,384,153”
Adicet Bio, Inc. shareholders approved Election of Class II Director Nominees at the 2026-06-17 meeting.
“Name Votes For Votes Withheld Broker Non-Votes Jeffrey Chodakewitz 4,629,969 732,047 1,384,153 Steve Dubin 4,596,116 765,900 1,384,153 Michael Grissinger 5,257,041 104,975 1,384,153”
Adicet Bio, Inc. reported first quarter ended March 31, 2026 results: net income Net loss for the three months ended March 31, 2026 was $20.2 million, or a net loss of $1.88 per basic and diluted share, EPS a net loss of $1.88 per basic and diluted share.
“On May 13, 2026, Adicet Bio, Inc. announced its financial results for the quarter ended March 31, 2026.”
Adicet Bio, Inc. issued pre-funded warrant to acquire 250,000 shares of Common Stock of warrant to RA Capital Management, L.P. and RA Capital Healthcare Fund, L.P. for exercise price of $0.0001 per share.
“On April 27, 2026, Adicet Bio, Inc. (the Company) entered into an exchange agreement with RA Capital Management, L.P. and RA Capital Healthcare Fund, L.P. (together, RA Capital) pursuant to which RA Capital exchanged 250,000 shares of the Company’s common stock, par value $0.0001 per share (Common Stock) for a pre-funded warrant (the Pre-Funded Warrant) to acquire 250,000 shares of Common Stock.”
Adicet Bio, Inc. issued 250,000 shares of the Company’s common stock of common stock to RA Capital Management, L.P. and RA Capital Healthcare Fund, L.P. for exchanged 250,000 shares of the Company’s common stock ... for a pre-funded warrant.
“On April 27, 2026, Adicet Bio, Inc. (the Company) entered into an exchange agreement with RA Capital Management, L.P. and RA Capital Healthcare Fund, L.P. (together, RA Capital) pursuant to which RA Capital exchanged 250,000 shares of the Company’s common stock, par value $0.0001 per share (Common Stock) for a pre-funded warrant (the Pre-Funded Warrant) to acquire 250,000 shares of Common Stock.”
Adicet Bio, Inc. reported three months ended December 31, 2025 results: net income $30.5 million, EPS $2.94 per basic and diluted share.
“Net loss for the three months ended December 31, 2025 was $30.5 million, or a net loss of $2.94 per basic and diluted share”
Adicet Bio, Inc.: Effective as of December 30, 2025, the Company filed a Certificate of Amendment to its Restated Certificate of Incorporation to effect a 1-for-16 reverse stock split of its common stock (effective 2025-12-30).
“On December 26, 2025, Adicet Bio, Inc. (the “Company”) filed an amendment (the “Certificate of Amendment”) to its Restated Certificate of Incorporation, to effectuate a reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”).”
Adicet Bio, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5550(a)(2), 5810(c)(3)(A)).
“October 7, 2025, the Company received a notice (the Extension Notice) from Nasdaq informing the Company that Nasdaq has granted the Company an additional 180 calendar days, or until April 6, 2026, to regain compliance with the Bid Price Requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In connection with the Extension Notice, the listing of the Common Stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective at the opening of business on October 9, 2025. The Extension Notice has no other immediate effect o”
Adicet Bio, Inc. announced a restructuring with charges of approximately $2.3 million (approximately 30% of the Company’s current employee base).
“On July 22, 2025, the Board of Directors of Adicet Bio, Inc. (the Company or Adicet) approved a reduction in its workforce by approximately 30% of the Company’s current employee base in connection with its strategic pipeline prioritization, as disclosed under Item 8.01 of this Current Report on Form 8-K. This workforce reduction will be substantially completed by the end of the third quarter of 2025. As a result of these actions, the Company expects to incur personnel-related restructuring charges of approximately $2.3 million in connection with one-time employee termination cash expenditures, including severance and other benefits, which are expected to be substantially incurred in the third quarter of 2025.”
Michael Grissinger was appointed as Director at Adicet Bio, Inc..
“On April 16, 2025, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Michael Grissinger to the Board, effective as of April 17, 2025, to fill the vacancy resulting from Dr. Gordon’s resignation.”
Carl L. Gordon resigned as Director at Adicet Bio, Inc..
“On April 14, 2025, Carl L. Gordon, Ph.D., a Class II member of the board of directors (the “Board”) of Adicet Bio, Inc. (the “Company”), notified the Company of his resignation from the Board and Compensation Committee of the Board (the “Compensation Committee”), effective on April 17, 2025.”
Adicet Bio, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“April 7, 2025, Adicet Bio, Inc. (the “Company”) received a notice from the Listing Qualifications staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) that because the closing bid price for the Company’s common stock had fallen below $1.00 per share for 30 consecutive business days, the Company no longer complied with the minimum bid price requirement for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Rule”). The letter does not result in the immediate delisting of the Company’s Common Stock, and the Company’s Common Stock will conti”
Lloyd Klickstein was appointed as Director at Adicet Bio, Inc..
“the Board appointed Lloyd Klickstein, M.D., Ph.D. to the Board, effective as of August 19, 2024, to fill the vacancy on the Board.”
Michael Kauffman resigned as Director at Adicet Bio, Inc..
“Michael Kauffman, M.D., Ph.D., a Class III member of the board of directors (the “Board”) of Adicet Bio, Inc. (the “Company”), notified the Company of his resignation from the Board and Nominating and Corporate Governance Committee (the “NCG Committee”), effective as of August 19, 2024.”
Adicet Bio, Inc. reported first quarter ended March 31, 2024 results: net income net loss of $28.0 million, EPS $0.35 per basic and diluted share.
“Net loss for the three months ended March 31, 2024 was $28.0 million, or a net loss of $0.35 per basic and diluted share”
Adicet Bio, Inc. entered into Sales Agreement with Jefferies LLC valued at 3.0% of the gross proceeds (effective 2024-03-22).
“On March 22, 2024, Adicet Bio, Inc. (the “Company”) entered into an Open Market Sales Agreement SM (the “Sales Agreement”) with Jefferies LLC (“Jefferies”) to sell shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), from time to time, through an “at the market” equity offering program under which Jefferies will act as sales agent or principal.”
Adicet Bio, Inc. reported fourth quarter and year ended December 31, 2023 results: net income Net loss for the three months ended December 31, 2023 was $29.5 million, or a net loss of $0.69 per basic and diluted sh, EPS $0.69 per basic and diluted share.
“On March 19, 2024, Adicet Bio, Inc. announced its financial results for the quarter and year ended December 31, 2023.”
Adicet Bio, Inc. entered into Underwriting Agreement with Jefferies LLC and Guggenheim Securities, LLC, as representatives of the several underwriters (effective 2024-01-22).
“On January 22, 2024, Adicet Bio, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Jefferies LLC and Guggenheim Securities, LLC, as representatives of the several underwriters listed on Schedule A thereto (the “Underwriters”), related to an underwritten public offering (the “Offering”) of 27,054,667 shares (the “Shares”) of common stock of the Company, par value $0.0001 per share (the “Common Stock”), and, in lieu of Common Stock to an investor, pre-funded warrants (the “Pre-Funded Warrants”) to purchase 8,445,333 shares of Common Stock (the “Warrant Shares”).”
Bastiano Sanna resigned as Director at Adicet Bio, Inc..
“On November 7, 2023 (the “Effective Date”), Bastiano Sanna, Ph.D., a current Class III member of the Board of Directors (the “Board”) of Adicet Bio, Inc. (the “Company”), notified the Company of his resignation from the Board and Audit Committee of the Board (“Audit Committee”), effective as of the Effective Date.”
Adicet Bio, Inc. reported the third quarter ended September 30, 2023 results: net income $49.9 million, EPS $1.16 per basic and diluted share.
“Net loss for the three months ended September 30, 2023 was $49.9 million, or a net loss of $1.16 per basic and diluted share”
Adicet Bio, Inc. reported the quarter ended June 30, 2023 results: net income $32.4 million, EPS $0.75 per basic and diluted share.
“Net loss for the three months ended June 30, 2023 was $32.4 million, or a net loss of $0.75 per basic and diluted share”
Katie Peng was appointed as Director at Adicet Bio, Inc..
“the Board appointed Katie Peng to the Board, effective as of July 10, 2023”
Adicet Bio, Inc. shareholders approved Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm at the 2023-06-01 meeting.
“Proposal 3 – Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm The stockholders of the Company ratified the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The results of the stockholders’ vote with respect to such ratification were as follows: Votes For Votes Against Abstain 35,860,385 12,396 3,044”
Adicet Bio, Inc. shareholders approved Approval of Adicet Bio, Inc. Second Amended and Restated 2018 Stock Option and Incentive Plan at the 2023-06-01 meeting.
“Proposal 2 – Approval of Adicet Bio, Inc. Second Amended and Restated 2018 Stock Option and Incentive Plan The stockholders of the Company approved the 2018 Plan. The results of the stockholders’ vote with respect to the approval of the 2018 Plan were as follows: Votes For Votes Against Abstain Broker Non-Votes 20,110,285 12,126,179 2,606 3,636,755”
Adicet Bio, Inc. shareholders approved Election of Class II Director Nominees at the 2023-06-01 meeting.
“Proposal 1 - Election of Class II Director Nominees The stockholders of the Company elected Carl L. Gordon, Ph.D., Steve Dubin, and Jeffrey Chodakewitz, M.D. as Class II directors of the Company, for a three-year term ending at the annual meeting of stockholders to be held in 2026 and until their successors have been duly elected and qualified or until their earlier resignation or removal. The results of the stockholders’ vote with respect to the election of the Class II directors were as follows: Name Votes For Votes Withheld Broker Non-Votes Carl L. Gordon, Ph.D. 23,974,856 8,264,214 3,636,755 Steve Dubin 25,969,684 6,269,386 3,636,755 Jeffrey Chodakewitz, M.D. 30,419,543 1,819,527 3,636,755”
Adicet Bio, Inc. amended Sixth Amendment with Pacific Western Bank (effective 2023-05-30).
“and Pacific Western Bank (“PacWest”) entered into a Sixth Amendment (the “Amendment”) to that certain Loan and Security Agreement, dated April 28, 2020”
Adicet Bio, Inc. reported the quarter ended March 31, 2023 results: net income Net loss for the three months ended March 31, 2023 was $30.9 million, or a net loss of $0.72 per basic and diluted share, EPS $0.72 per basic and diluted share.
“Adicet Bio, Inc. announced its financial results for the quarter ended March 31, 2023.”
Adicet Bio, Inc. reported for the fourth quarter and year ended December 31, 2022 results: net income Net loss for the three months ended December 31, 2022 was $29.9 million, EPS a net loss of $0.72 per basic and diluted share.
“Adicet Bio, Inc. announced its financial results for the quarter and year ended December 31, 2022.”
Adicet Bio, Inc. amended Fifth Amendment to Loan and Security Agreement with Pacific Western Bank ("PacWest") (effective 2022-12-02).
“On December 2, 2022 (the “Effective Date”), Adicet Therapeutics, Inc. (the “Subsidiary”), a Delaware corporation and wholly-owned subsidiary of Adicet Bio, Inc. (the “Guarantor”, and together with the Subsidiary, the “Company”), and Pacific Western Bank (“PacWest”) entered into a Fifth Amendment (the “Amendment”) to that certain Loan and Security Agreement, dated April 28, 2020, by and among the Subsidiary and PacWest (the “Agreement”).”
Adicet Bio, Inc. reported the third quarter ended September 30, 2022 results: net income Net loss for the three months ended September 30, 2022 was $22.0 million, or a net loss of $0.53 per basic and diluted s, EPS net loss of $0.53 per basic and diluted share.
“Net loss for the three months ended September 30, 2022 was $22.0 million, or a net loss of $0.53 per basic and diluted share”
Michael Kauffman was appointed as Director at Adicet Bio, Inc..
“On November 17, 2021, upon the recommendation of the Nominating and Corporate Governance Committee (the “NCG Committee”) of the board of directors (the “Board”) of Adicet Bio, Inc. (the “Company”), the Board appointed Michael Kauffman, M.D., Ph.D., to join the Board, effective as of November 17, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.